2023
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia
Podoltsev N, Wang R, Shallis R, Stempel J, Di M, Neparidze N, Zeidan A, Huntington S, Giri S, Hull S, Gore S, Ma X. Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. Cancer Medicine 2023, 12: 18889-18900. PMID: 37702132, PMCID: PMC10557879, DOI: 10.1002/cam4.6528.Peer-Reviewed Original ResearchConceptsIncidence of thrombosisPolycythemia veraEssential thrombocythemiaStatin useOlder adultsEnd Results-Medicare databasePopulation-based cohort studyArterial thrombotic eventsSurvival of patientsUse of statinsClaims-based studyRisk of thrombosisCardiovascular morbidityCause mortalityTreatment weighting (IPTW) approachCohort studyOlder patientsOverall survivalThrombotic eventsVenous thrombosisPatient populationPrevious registryStatinsTherapeutic strategiesET subgroup
2020
Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents
Giri S, Huntington SF, Wang R, Zeidan AM, Podoltsev N, Gore SD, Ma X, Gross CP, Davidoff AJ, Neparidze N. Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. Blood Advances 2020, 4: 2245-2253. PMID: 32442299, PMCID: PMC7252537, DOI: 10.1182/bloodadvances.2019001425.Peer-Reviewed Original ResearchConceptsHigh-risk chromosomal abnormalitiesOverall survivalMultiple myelomaChromosome 1 abnormalitiesCox proportional hazards regression modelHigh-risk multiple myelomaProportional hazards regression modelsFlatiron Health databaseR-ISS stageMedian overall survivalFirst-line therapyDays of diagnosisInferior overall survivalInternational Staging SystemKaplan-Meier methodSurvival of patientsWorse overall survivalLog-rank testHazards regression modelsCommon genetic aberrationsElectronic health recordsEligible patientsContemporary cohortImmunomodulatory agentsStaging system